Exosomes Market Overview
Exosomes are small extracellular vesicles, roughly 40–160 nm in size, released by most cell types through fusion of multivesicular bodies with the plasma membrane. Present in biological fluids such as blood, urine, breast milk, and semen, they carry proteins, lipids, nucleic acids, and metabolites that reflect their cell of origin. This cargo-transfer capability makes the exosomes pipeline a growing focus for both diagnostic and therapeutic innovation. Their natural biocompatibility, low immunogenicity, and ability to cross biological barriers like the blood-brain barrier position exosomes as promising vehicles for targeted drug delivery, liquid biopsy applications, and regenerative medicine across oncology, neurology, and organ-specific disease areas.
Learn more about Exosomes clinical trials and key company profiles
Exosomes Biogenesis and Mechanism of Action
Exosomes form through a double invagination of the plasma membrane, generating multivesicular bodies (MVBs) containing intraluminal vesicles (ILVs) that are later released upon membrane fusion. This process begins with early-sorting endosomes maturing into late endosomes and MVBs, incorporating components from the endoplasmic reticulum and Golgi apparatus. Proteins such as ESCRT complexes, Rab GTPases, ALIX, and tetraspanins regulate cargo sorting, membrane budding, and vesicle release through ESCRT-dependent and independent pathways, enabling secretion into body fluids via constitutive or stress-induced pathways.
Explore the full Exosomes pipeline report and emerging therapy insights
Exosomes Pipeline Emerging Therapies
The exosomes pipeline landscape features over 110 pipeline drugs from 100+ companies. Capricor Therapeutics’ CAP-1002 leverages cardiosphere-derived cells that release exosomes influencing immune responses and tissue repair, currently in registration for Duchenne Muscular Dystrophy. BrainStorm Cell Therapeutics’ debamestrocel (NurOwn) uses MSC-NTF cells delivering neurotrophic factors via exosome-based mechanisms, in Phase III for Amyotrophic Lateral Sclerosis. Aegle Therapeutics’ AGLE-102, an allogeneic MSC-derived vesicle therapy, is in Phase I/II for burns and Epidermolysis Bullosa Dystrophica. Additional candidates include RION’s RioMSK001 (Phase I, Knee Osteoarthritis) and ExoStemTech’s HEPATOSOME (preclinical, Liver Fibrosis).
Exosomes Therapeutic and Clinical Trial Assessment
The report segments the exosomes pipeline by product type, clinical stage, route of administration, and molecule type. Coverage spans late-stage (Phase III), mid-stage (Phase II), early-stage (Phase I), preclinical, discovery, and discontinued/inactive candidates. Routes of administration include oral, intravenous, subcutaneous, parenteral, and topical, while molecule types range from recombinant fusion proteins and small molecules to monoclonal antibodies, peptides, polymers, and gene therapies.
Key Exosomes Companies and Products
Leading players developing exosome-based therapeutics include Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, ILIAS Biologics, Secretome Therapeutics, Everzom, Brexogen, Exogenus Therapeutics, Coya Therapeutics, and NurExone. Key products in development include CAP-1002, Debamestrocel, AGLE-102, EXOB-001, SNE-101, ILB 202, STM-01, COYA 201, and ExoPTEN therapy, reflecting the breadth of the current exosomes pipeline.
Recent Developments in the Exosomes Pipeline
- Capricor Therapeutics advanced CAP-1002 to the registration stage for Duchenne Muscular Dystrophy
- BrainStorm Cell Therapeutics progressed debamestrocel through Phase III for Amyotrophic Lateral Sclerosis, with additional neurological programs in earlier stages
- Aegle Therapeutics expanded AGLE-102 development into preclinical evaluation for Graft-versus-Host Disease alongside its Phase I/II burns and Epidermolysis Bullosa Dystrophica programs
Get detailed Exosomes pipeline analysis and unmet needs assessment
Conclusion
The exosomes pipeline reflects a rapidly diversifying field, with over 100 companies advancing more than 110 drug candidates across oncology, neurology, musculoskeletal, and rare disease indications. Lead programs like CAP-1002 and debamestrocel illustrate how exosome biology is translating into late-stage clinical progress, while earlier-stage candidates such as RioMSK001 and HEPATOSOME signal continued expansion into new therapeutic areas. With diverse molecule types, routes of administration, and active collaboration activity, the competitive landscape is expected to evolve significantly through 2026 as more programs move from preclinical evaluation toward registration and eventual commercialization.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
